January 31, 2017 07:33 AM ESTUpdated 03:37 PM
Bioregnum
Opinion

Big Phar­ma CEOs get a face-to-face with Trump and a shot at a ne­go­ti­at­ed cease fire

On Mon­day, as CEOs in the biotech in­dus­try chimed in to crit­i­cize Don­ald Trump’s trav­el ban for 7 Mus­lim coun­tries, the top fig­ures from …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times